Heron Therapeutics Inc (HRTX) — Titan Protect Analysis

HRTX

Heron Therapeutics Inc

Healthcare · ·

$0.43

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$85M

Total market value of the company

Trailing P/E

N/A

Forward P/E

0.00

Based on estimated future earnings — lower means cheaper

Rev Growth

-10.8%

Year-over-year revenue change

Profit Margin

-20.5%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$4.00

+830% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 3 analysts covering this stock

About Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed na

https://www.herontx.com

Country: United States Employees: 128 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.725

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.1419

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.734

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-64.8%

Historical annualised return based on price data

Max Drawdown

-88.2%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.71

Significantly more volatile than the market

52W High

$2.30

81% below the year high

52W Low

$0.44

-3% above the year low

Avg Volume

2,442,619

Average daily shares traded — higher means easier to buy and sell

Short Ratio

15.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.18

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

1,550.12

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

62.8%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-13.7%

Profit from core operations before interest and tax

Free Cash Flow

$-18,442,250

Negative — the business is spending more than it generates

Revenue (TTM)

$151M

Total revenue over the last 12 months

Net Income

$-30,941,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$4.00

Target Median

$4.00

Target Low

$3.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go